Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| Yesterday 5:48 PM View:  | Gassert Chad SVP - CORP. DEV. & STRATEGY | BioSante Pharmaceuticals, I... (ANIP) | 01-May-24 | Private Sale (Planned) | 20,000 | $66.62 | $1,332,400.00 | (7%) 302.9K to 282.9K | |
| 22-Apr-24 6:26 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 19-Apr-24 | Sale (Planned) | 16,809 | $65.17 | $1,095,440.00 | (2%) 873.08K to 856.27K | |
| 22-Apr-24 6:26 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 18-Apr-24 | Private Sale (Planned) | 10,423 | $64.98 | $677,287.00 | (1%) 883.5K to 873.08K | |
| 17-Apr-24 4:33 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 17-Apr-24 | Sale (Planned) | 9,520 | $65.40 | $622,608.00 | (1%) 893.02K to 883.5K | |
| 17-Apr-24 4:33 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 16-Apr-24 | Sale (Planned) | 5,834 | $66.20 | $386,211.00 | (< 1%) 898.86K to 893.02K | |
| 17-Apr-24 4:33 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 15-Apr-24 | Private Sale (Planned) | 7,414 | $66.33 | $491,771.00 | (< 1%) 906.27K to 898.86K | |
| 15-Apr-24 6:28 PM View: | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | BioSante Pharmaceuticals, I... (ANIP) | 12-Apr-24 | Private Sale (Planned) | 250 | $67.79 | $16,947.50 | (< 1%) 59.98K to 59.73K | |
| 11-Apr-24 9:12 PM View: | Carey Stephen P. SVP & CFO | BioSante Pharmaceuticals, I... (ANIP) | 10-Apr-24 | Payment of Exercise | 4,534 | $66.96 | $303,597.00 | (3%) 171.5K to 166.97K | |
| 11-Apr-24 9:13 PM View: | Marken James G. SVP Ops & Prod Dev | BioSante Pharmaceuticals, I... (ANIP) | 10-Apr-24 | Payment of Exercise | 2,799 | $66.96 | $187,421.00 | (2%) 118.81K to 116.01K | |
| 02-Apr-24 6:59 PM View: | Gassert Chad SVP - CORP. DEV. & STRATEGY | BioSante Pharmaceuticals, I... (ANIP) | 01-Apr-24 | Private Sale (Planned) | 20,000 | $67.25 | $1,345,000.00 | (6%) 322.9K to 302.9K | |
| 25-Mar-24 4:09 PM View: | Lalwani Nikhil PRESIDENT & CEO Director | BioSante Pharmaceuticals, I... (ANIP) | 23-Mar-24 | Payment of Exercise | 17,455 | $69.58 | $1,214,520.00 | (4%) 411.63K to 394.17K | |
| 25-Mar-24 4:17 PM View: | Carey Stephen P. SVP & CFO | BioSante Pharmaceuticals, I... (ANIP) | 23-Mar-24 | Payment of Exercise | 6,210 | $69.58 | $432,092.00 | (3%) 177.71K to 171.5K | |
| 25-Mar-24 4:14 PM View: | Marken James G. SVP Ops & Prod Dev | BioSante Pharmaceuticals, I... (ANIP) | 23-Mar-24 | Payment of Exercise | 3,653 | $69.58 | $254,176.00 | (3%) 122.46K to 118.81K | |
| 13-Mar-24 4:48 PM View: | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | BioSante Pharmaceuticals, I... (ANIP) | 13-Mar-24 | Private Sale (Planned) | 250 | $66.54 | $16,635.00 | (< 1%) 60.23K to 59.98K | |
| 13-Mar-24 4:44 PM View: | Gassert Chad SVP - CORP. DEV. & STRATEGY | BioSante Pharmaceuticals, I... (ANIP) | 11-Mar-24 | Private Sale (Planned) | 20,000 | $65.81 | $1,316,200.00 | (6%) 342.9K to 322.9K | |
| 11-Mar-24 6:39 PM View: | Carey Stephen P. SVP & CFO | BioSante Pharmaceuticals, I... (ANIP) | 11-Mar-24 | Sale | 7,787 | $65.55 | $510,438.00 | (4%) 185.5K to 177.71K | |
| 08-Mar-24 7:25 PM View: | Lalwani Nikhil PRESIDENT & CEO Director | BioSante Pharmaceuticals, I... (ANIP) | 08-Mar-24 | Sale | 16,292 | $67.13 | $1,093,680.00 | (4%) 427.92K to 411.63K | |
| 11-Mar-24 6:43 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 08-Mar-24 | Private Sale (Planned) | 10,000 | $67.17 | $671,700.00 | (1%) 916.27K to 906.27K | |
| 08-Mar-24 7:25 PM View: | Lalwani Nikhil PRESIDENT & CEO Director | BioSante Pharmaceuticals, I... (ANIP) | 07-Mar-24 | Payment of Exercise | 17,060 | $66.71 | $1,138,070.00 | (4%) 444.98K to 427.92K | |
| 11-Mar-24 6:39 PM View: | Carey Stephen P. SVP & CFO | BioSante Pharmaceuticals, I... (ANIP) | 07-Mar-24 | Payment of Exercise | 4,216 | $66.71 | $281,249.00 | (2%) 189.72K to 185.5K | |
| 07-Mar-24 9:42 PM View: | Marken James G. SVP Ops & Prod Dev | BioSante Pharmaceuticals, I... (ANIP) | 07-Mar-24 | Payment of Exercise | 2,034 | $66.71 | $135,688.00 | (1%) 148.83K to 146.8K | |
| 07-Mar-24 9:16 PM View: | Mutz Christopher HEAD OF RARE DISEASE | BioSante Pharmaceuticals, I... (ANIP) | 07-Mar-24 | Payment of Exercise | 2,110 | $66.71 | $140,758.00 | (2%) 87.39K to 85.28K | |
| 07-Mar-24 9:11 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 07-Mar-24 | Sale (Planned) | 15,085 | $66.35 | $1,000,890.00 | (2%) 931.36K to 916.27K | |
| 07-Mar-24 9:42 PM View: | Marken James G. SVP Ops & Prod Dev | BioSante Pharmaceuticals, I... (ANIP) | 07-Mar-24 | Sale | 24,338 | $66.37 | $1,615,310.00 | (17%) 146.8K to 122.46K | |
| 07-Mar-24 9:21 PM View: | Gutwerg Ori SVP, GENERICS | BioSante Pharmaceuticals, I... (ANIP) | 07-Mar-24 | Payment of Exercise | 2,494 | $66.71 | $166,375.00 | (3%) 82.71K to 80.21K | |
| 07-Mar-24 9:11 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 06-Mar-24 | Sale (Planned) | 14,822 | $65.47 | $970,396.00 | (2%) 946.18K to 931.36K | |
| 08-Mar-24 7:25 PM View: | Lalwani Nikhil PRESIDENT & CEO Director | BioSante Pharmaceuticals, I... (ANIP) | 06-Mar-24 | Private Sale | 28,965 | $65.52 | $1,897,790.00 | (6%) 473.95K to 444.98K | |
| 06-Mar-24 4:24 PM View: | Mutz Christopher HEAD OF RARE DISEASE | BioSante Pharmaceuticals, I... (ANIP) | 05-Mar-24 | Private Sale | 5,000 | $66.00 | $330,000.00 | (5%) 92.39K to 87.39K | |
| 07-Mar-24 9:11 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 05-Mar-24 | Private Sale (Planned) | 10,093 | $65.35 | $659,578.00 | (1%) 956.27K to 946.18K | |
| 06-Mar-24 4:20 PM View: | Pera Antonio R Director | BioSante Pharmaceuticals, I... (ANIP) | 04-Mar-24 | Private Sale | 7,000 | $65.20 | $456,400.00 | (21%) 33.63K to 26.63K | |
| 01-Mar-24 4:59 PM View: | Davis Krista SVP, CHIEF HR OFFICER | BioSante Pharmaceuticals, I... (ANIP) | 29-Feb-24 | Payment of Exercise | 1,173 | $67.67 | $79,376.90 | (2%) 52.72K to 51.55K | |
| 01-Mar-24 5:12 PM View: | Mutz Christopher HEAD OF RARE DISEASE | BioSante Pharmaceuticals, I... (ANIP) | 29-Feb-24 | Payment of Exercise | 1,275 | $67.67 | $86,279.20 | (1%) 93.66K to 92.39K | |
| 01-Mar-24 5:03 PM View: | Gutwerg Ori SVP, GENERICS | BioSante Pharmaceuticals, I... (ANIP) | 29-Feb-24 | Payment of Exercise | 1,570 | $67.67 | $106,242.00 | (2%) 84.28K to 82.71K | |
| 01-Mar-24 5:18 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 29-Feb-24 | Payment of Exercise | 1,122 | $67.67 | $75,925.70 | (< 1%) 957.39K to 956.27K | |
| 01-Mar-24 5:06 PM View: | Lalwani Nikhil PRESIDENT & CEO Director | BioSante Pharmaceuticals, I... (ANIP) | 29-Feb-24 | Payment of Exercise | 10,014 | $67.67 | $677,647.00 | (2%) 483.96K to 473.95K | |
| 01-Mar-24 4:55 PM View: | Carey Stephen P. SVP & CFO | BioSante Pharmaceuticals, I... (ANIP) | 29-Feb-24 | Payment of Exercise | 1,914 | $67.67 | $129,520.00 | (< 1%) 191.63K to 189.72K | |
| 01-Mar-24 5:09 PM View: | Marken James G. SVP Ops & Prod Dev | BioSante Pharmaceuticals, I... (ANIP) | 29-Feb-24 | Payment of Exercise | 1,058 | $67.67 | $71,594.90 | (< 1%) 149.89K to 148.83K | |
| 01-Mar-24 5:01 PM View: | Gassert Chad SVP - CORP. DEV. & STRATEGY | BioSante Pharmaceuticals, I... (ANIP) | 29-Feb-24 | Payment of Exercise | 1,635 | $67.67 | $110,640.00 | (< 1%) 344.54K to 342.9K | |
| 01-Mar-24 4:57 PM View: | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | BioSante Pharmaceuticals, I... (ANIP) | 29-Feb-24 | Payment of Exercise | 1,173 | $67.67 | $79,376.90 | (2%) 61.4K to 60.23K | |
| 20-Feb-24 5:09 PM View: | Gutwerg Ori SVP, GENERICS | BioSante Pharmaceuticals, I... (ANIP) | 15-Feb-24 | Payment of Exercise | 1,244 | $57.55 | $71,592.20 | (1%) 85.52K to 84.28K | |
| 20-Feb-24 5:02 PM View: | Mutz Christopher HEAD OF RARE DISEASE | BioSante Pharmaceuticals, I... (ANIP) | 15-Feb-24 | Payment of Exercise | 1,261 | $57.55 | $72,570.50 | (1%) 94.92K to 93.66K | |
| 16-Feb-24 4:53 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 14-Feb-24 | Grant | 22,367 | -- | -- | 2% 935.03K to 957.39K | |
| 16-Feb-24 4:56 PM View: | Lalwani Nikhil PRESIDENT & CEO Director | BioSante Pharmaceuticals, I... (ANIP) | 14-Feb-24 | Grant | 134,216 | -- | -- | 38% 349.74K to 483.96K | |
| 16-Feb-24 4:26 PM View: | Carey Stephen P. SVP & CFO | BioSante Pharmaceuticals, I... (ANIP) | 14-Feb-24 | Grant | 35,790 | -- | -- | 23% 155.84K to 191.63K | |
| 16-Feb-24 4:50 PM View: | Mutz Christopher HEAD OF RARE DISEASE | BioSante Pharmaceuticals, I... (ANIP) | 14-Feb-24 | Grant | 31,316 | -- | -- | 49% 63.61K to 94.92K | |
| 16-Feb-24 4:47 PM View: | Marken James G. SVP Ops & Prod Dev | BioSante Pharmaceuticals, I... (ANIP) | 14-Feb-24 | Grant | 16,776 | -- | -- | 13% 133.11K to 149.89K | |
| 16-Feb-24 4:34 PM View: | Gassert Chad SVP - CORP. DEV. & STRATEGY | BioSante Pharmaceuticals, I... (ANIP) | 14-Feb-24 | Grant | 22,367 | -- | -- | 7% 322.17K to 344.54K | |
| 16-Feb-24 4:28 PM View: | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | BioSante Pharmaceuticals, I... (ANIP) | 14-Feb-24 | Grant | 24,605 | -- | -- | 67% 36.8K to 61.4K | |
| 16-Feb-24 4:30 PM View: | Davis Krista SVP, CHIEF HR OFFICER | BioSante Pharmaceuticals, I... (ANIP) | 14-Feb-24 | Grant | 20,131 | -- | -- | 62% 32.59K to 52.72K | |
| 16-Feb-24 4:38 PM View: | Gutwerg Ori SVP, GENERICS | BioSante Pharmaceuticals, I... (ANIP) | 14-Feb-24 | Grant | 24,605 | -- | -- | 40% 60.91K to 85.52K |
